SELLAS Life Sciences (SLS) Net Income Growth (5y) (2016 - 2026)

SELLAS Life Sciences (SLS) Net Income Growth (5y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 SELLAS Life Sciences 1.89 Bn 1.78 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -45.04%
Dec 31, 2025 -14.43%
Sep 30, 2025 -9.66%
Jun 30, 2025 -15.38%
Mar 31, 2025 -8.51%
Dec 31, 2022 -2.20%
Sep 30, 2022 -129.31%
Jun 30, 2022 -46.29%
Mar 31, 2022 -12.28%
Dec 31, 2021 -20.59%
Sep 30, 2021 -22.30%
Jun 30, 2021 -9.52%
Mar 31, 2021 7.11%
Dec 31, 2020 -16.04%
Sep 30, 2020 17.02%
Jun 30, 2020 -14.84%
Mar 31, 2020 -13.29%
Jun 30, 2017 -25.21%
Mar 31, 2017 -50.53%
Dec 31, 2016 63.76%